Skip to main content
Premium Trial:

Request an Annual Quote

Start-up Illumigen Biosciences Develops New Genome Analysis Platform

NEW YORK, Feb 1 – Illumigen Biosciences, a start-up applied genomics company in Seattle, Wash., has unveiled a new computing platform for analyzing the human genome, the company said Thursday.

The system, GeneLamp, compares experimental data from Illumigen’s in-house laboratories with data from “a variety” of genomics databases to search for drug targets, according to the company.

The system will be incorporated into Illumigen's in-house experiments, which identify DNA sequence and gene expression data using proprietary population access programs.

“This program aims to speed our discovery efforts by increasing the efficiency with which we can evaluate and prioritize promising new drug targets,” Charles Magness, Illumigen's chief information officer, said in a statement.

 

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.